DNA binding, antitubercular, antibacterial and anticancer studies of newly designed piano-stool ruthenium(ii) complexes. Issue 42 (17th October 2022)

• Record Type: Journal Article
• Authors: Navale, Govinda; Singh, Sain; Agrawal, Sonia; Ghosh, Chandrachur; Roy Choudhury, Angshuman; Roy, Partha; Sarkar, Dhiman; Ghosh, Kaushik
• Is Part Of: Dalton transactions. Volume 51:Issue 42(2022)
• Page Start: 16371
• Page End: 16382
• Publication Date: 2022-10-17
• Subjects: Chemistry, Inorganic -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemistry, Inorganic -- Periodicals; 546.05
• DOI: 10.1039/d2dt02577a
• Languages: English
• ISSNs: 1477-9226

Abstract

Abstract : The chemotherapeutic potential of ruthenium(ii ) complexes as DNA binding, antitubercular, antibacterial, and anticancer agents. Abstract : The chemotherapeutic potential of ruthenium(ii ) complexes has recently attracted researchers' interest as antibacterial and anticancer agents. In this study, two novel half-sandwich imine-based Ru complexes ([Ru( p -cymene)Cl(L-1)][PF6 ] (Ru-1) and [Ru( p -cymene)Cl(L-2)][PF6 ] (Ru-2)) were reported for their deoxyribonucleic acid (DNA) binding and antitubercular, antibacterial, and anticancer activities. The molecular structure of Ru-2 was obtained by single-crystal X-ray crystallography. DNA interaction studies were conducted by UV-Vis absorbance and fluorescence spectral titration which gave rise to DNA binding constants ( K b ) of 1.32 × 10 6 and 1.82 × 10 6 for Ru-1 and Ru-2, respectively and the Stern–Volmer binding constant ( K SV ) values for Ru-1 and Ru-2 were 1.7763 × 10 4 M −1 and 7.6 × 10 3 M −1, respectively. The in vitro antitubercular activity was evaluated against Mycobacterium tuberculosis H37Ra. The antibacterial potential of both the Ru-complexes was examined against Gram-negative ( Escherichia coli and Pseudomonas aeruginosa ) and Gram-positive ( Staphylococcus aureus and Bacillus subtilis ) bacteria. The half-maximal inhibitory concentration (IC50 ) values for the antitubercular activity of Ru-1 and Ru-2 were 4.87 ± 1.32 μM and 5.78 ± 0.54 μM, respectively. A cytotoxic study of these complexes was performed against the human breast cancer cell line (MCF-7) and the human embryonic kidney cell line (HEK293) (normal cells). The study revealed meaningful activity of the Ru-1 complex against (cancer) MCF-7 cells, while the viability of HEK293 (normal) cells in the presence of Ru-2 was higher as compared to a reference drug 5FU. We suggest that these kinds of Ru-complexes could have potential for application in metallopharmaceuticals.